These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23811841)

  • 1. Cardiac resynchronization therapy: implant rates, temporal trends and relationships with heart failure epidemiology.
    Boriani G; Berti E; Belotti LM; Biffi M; Carboni A; Bandini A; Casali E; Tomasi C; Toselli T; Baraldi P; Bottoni N; Barbato G; Sassone B;
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):147-54. PubMed ID: 23811841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facility-Level Variation and Clinical Outcomes in Use of Cardiac Resynchronization Therapy With and Without an Implantable Cardioverter-Defibrillator.
    Kramer DB; Normand ST; Volya R; Hatfield LA
    Circ Cardiovasc Qual Outcomes; 2018 Dec; 11(12):e004763. PubMed ID: 30562069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry.
    Morani G; Gasparini M; Zanon F; Casali E; Spotti A; Reggiani A; Bertaglia E; Solimene F; Molon G; Accogli M; Tommasi C; Paoletti Perini A; Ciardiello C; Padeletti L
    Europace; 2013 Sep; 15(9):1273-9. PubMed ID: 23439866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of community wealth on use of cardiac-resynchronization therapy with defibrillators for heart failure patients.
    Farmer SA; Tuohy EJ; Small DS; Wang Y; Groeneveld PW
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):798-807. PubMed ID: 23093561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac device therapy in patients with left ventricular dysfunction and heart failure: 'real-world' data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital).
    Boriani G; Berti E; Belotti LM; Biffi M; De Palma R; Malavasi VL; Bottoni N; Rossi L; De Maria E; Mantovan R; Zardini M; Casali E; Marconi M; Bandini A; Tomasi C; Boggian G; Barbato G; Toselli T; Zennaro M; Sassone B;
    Eur J Heart Fail; 2016 Jun; 18(6):693-702. PubMed ID: 27060289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association.
    Raatikainen MJ; Arnar DO; Merkely B; Camm AJ; Hindricks G
    Europace; 2016 Aug; 18 Suppl 3():iii1-iii79. PubMed ID: 27496955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five year trends (2008-2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases.
    Banks H; Torbica A; Valzania C; Varabyova Y; Prevolnik Rupel V; Taylor RS; Hunger T; Walker S; Boriani G; Fattore G;
    Europace; 2018 Apr; 20(4):643-653. PubMed ID: 29016747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).
    Healey JS; Hohnloser SH; Exner DV; Birnie DH; Parkash R; Connolly SJ; Krahn AD; Simpson CS; Thibault B; Basta M; Philippon F; Dorian P; Nair GM; Sivakumaran S; Yetisir E; Wells GA; Tang AS;
    Circ Heart Fail; 2012 Sep; 5(5):566-70. PubMed ID: 22896584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.
    Gadler F; Valzania C; Linde C
    Europace; 2015 Jan; 17(1):69-77. PubMed ID: 25336667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database.
    Boriani G; Ritter P; Biffi M; Ziacchi M; Diemberger I; Martignani C; Valzania C; Valsecchi S; Padeletti L; Gadler F
    Europace; 2016 Sep; 18(9):1366-73. PubMed ID: 26847076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, predictors, and procedural results of upgrade to resynchronization therapy: the RAFT upgrade substudy.
    Essebag V; Joza J; Birnie DH; Sapp JL; Sterns LD; Philippon F; Yee R; Crystal E; Kus T; Rinne C; Healey JS; Sami M; Thibault B; Exner DV; Coutu B; Simpson CS; Wulffhart Z; Yetisir E; Wells G; Tang AS
    Circ Arrhythm Electrophysiol; 2015 Feb; 8(1):152-8. PubMed ID: 25417892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States.
    Patel N; Viles-Gonzalez J; Agnihotri K; Arora S; Patel NJ; Aneja E; Shah M; Badheka AO; Pothineni NV; Kancharla K; Mulpuru S; Noseworthy PA; Kusumoto F; Cha YM; Deshmukh AJ
    J Cardiovasc Electrophysiol; 2018 Oct; 29(10):1425-1435. PubMed ID: 30016005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
    Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
    Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead extraction: The road to successful cardiac resynchronization therapy.
    Maciąg A; Syska P; Sterliński M; Przybylski A; Sitkowska E; Oręziak A; Bilińska M; Kuśmierczyk M; Szwed H
    Cardiol J; 2015; 22(2):188-93. PubMed ID: 25299498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cardiac resynchronization therapy on hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure trial.
    Gillis AM; Kerr CR; Philippon F; Newton G; Talajic M; Froeschl M; Froeschl S; Swiggum E; Yetisir E; Wells GA; Tang AS
    Circulation; 2014 May; 129(20):2021-30. PubMed ID: 24610807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France.
    Galand V; Linde C; Lellouche N; Mansourati J; Deharo JC; Sagnol P; Da Costa A; Horvilleur J; Defaye P; Boveda S; Steinbach M; Bru P; Rumeau P; Beard T; Younsi S; Dickstein K; Normand C; Leclercq C
    Arch Cardiovasc Dis; 2019 Nov; 112(11):713-722. PubMed ID: 31706879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Resynchronization Therapy: US Trends and Disparities in Utilization and Outcomes.
    Sridhar AR; Yarlagadda V; Parasa S; Reddy YM; Patel D; Lakkireddy D; Wilkoff BL; Dawn B
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003108. PubMed ID: 26921376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Awareness of indications for device therapy among a broad range of physicians: a survey study.
    Hübinette C; Lund LH; Gadler F; Ståhlberg M
    Europace; 2014 Nov; 16(11):1580-6. PubMed ID: 24451291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.
    Wilcox JE; Fonarow GC; Zhang Y; Albert NM; Curtis AB; Gheorghiade M; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW
    Circ Heart Fail; 2014 Jan; 7(1):146-53. PubMed ID: 24178311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.